Katrien De Wolf

Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma

Nora Sundahl, Katrien De Wolf, Vibeke Kruse (UGent) , Annabel Meireson (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Mireille Van Gele (UGent) , Reinhart Speeckaert (UGent) , Benjamin Hennart, Lieve Brochez (UGent) , et al.

(2018) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 100(4). p.906-915

Add to list

Journal Article
A1
open access

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma : a phase I dose escalation trial

Katrien De Wolf, Sylvie Rottey (UGent) , Karim Vermaelen (UGent) , Karel Decaestecker (UGent) , Nora Sundahl, Lizzy De Lobel (UGent) , Els Goetghebeur (UGent) , Gert De Meerleer (UGent) , Nicolaas Lumen (UGent) , Valerie Fonteyne (UGent) , et al.

(2017) RADIATION ONCOLOGY. 12.

Add to list

Journal Article
A1
open access

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma : evaluation of clinical and immunologic response

Katrien De Wolf, VIBEKE KRUSE (UGent) , Nora Sundahl, Mireille Van Gele (UGent) , INES CHEVOLET (UGent) , Reinhart Speeckaert (UGent) , Lieve Brochez (UGent) and Piet Ost (UGent)

(2017) JOURNAL OF TRANSLATIONAL MEDICINE. 15.

Add to list

Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial

Dieter Berwouts (UGent) , Katrien De Wolf, Wilfried De Neve (UGent) , Ana Maria Luiza Olteanu (UGent) , Bieke Lambert (UGent) , Bruno Speleers (UGent) , Ingeborg Goethals (UGent) , Indira Madani (UGent) and Piet Ost (UGent)

(2017) JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY. 61(1). p.124-132

Add to list

Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: dose limiting toxicity and abscopal effect

Katrien De Wolf, Piet Ost (UGent) , VIBEKE KRUSE (UGent) , Lieve Brochez (UGent) and INES CHEVOLET (UGent)

(2015) ANNALS OF ONCOLOGY. 26(suppl. 8). p.7-7

Add to list

Journal Article
A1
open access

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy

Katrien De Wolf, Karim Vermaelen (UGent) , Gert De Meerleer (UGent) , Bart Lambrecht (UGent) and Piet Ost (UGent)

(2015) ONCOIMMUNOLOGY. 4(10).

Add to list

Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: a 3-arm randomized phase II trial

Dieter Berwouts (UGent) , Katrien De Wolf, Bieke Lambert (UGent) , Renée Bultijnck (UGent) , Wilfried De Neve (UGent) , Lizzy De Lobel (UGent) , Lennart Jans (UGent) , Els Goetghebeur (UGent) , Bruno Speleers (UGent) , Ana Maria Luiza Olteanu (UGent) , et al.

(2015) RADIOTHERAPY AND ONCOLOGY. 115(2). p.272-278

Academic Bibliography

Katrien De Wolf

Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma : a phase I dose escalation trial

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma : evaluation of clinical and immunologic response

Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial

Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: dose limiting toxicity and abscopal effect

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy

Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: a 3-arm randomized phase II trial

Contents

Support

Contact